INVITRO INTERNATIONAL

QUARTERLY DISCLOSURE STATEMENT AS OF JUNE 30, 2018

According to OTC Pink Basic Disclosure Guidelines (v1.1 April 25, 2013)

1) Name of the Issuer and its Predecessors (if any)

The issuer's name is InVitro International (hereinafter referred to as the "Company"). The Company has not used any other names during the past five years.

2) Address of the Issuer's Principal Executive Offices.

Company Headquarters

Address: 330 E. Orangethorpe Avenue, Suite D, Placentia, CA 92870
Phone: 949-851-8356
Email: invitro@invitrointl.com
Website: www.invitrointl.com

IR Contact

The Company currently does not have an investor relations contact.

3) Security Information

Trading Symbol: IVRO
Exact title and class of securities outstanding: Common Stock
CUSIP: 461853103
Par or Stated Value: None
Total shares authorized: 40,000,000 as of June 30, 2018
Total shares outstanding: 22,016,059 as of June 30, 2018

Additional class of securities (if necessary)

The Company currently has 1,000,000 shares of no par preferred stock authorized. The shares may be issued in the future in one or more series as determined by the Company's Board of Directors. No shares of preferred stock are outstanding. Prior to issuance, the Board of Directors may set the dividend rate, the cumulative or non-cumulative nature of the dividends, and the redemption, liquidation, conversion and voting rights of the shares.

The Company also has three stock option plans authorized pursuant to which an aggregate of 1,800,000 shares of Common Stock may be issued upon exercise of incentive stock options or nonqualified stock options granted to employees, directors, officers, and other service providers. Currently, there are no outstanding options.

Transfer Agent

Name: Pacific Stock Transfer Company
Address: 6725 Via Austi Parkway, Suite 300, Las Vegas, NV 89119 Phone: 702-361-3033

The Transfer Agent is registered with the Securities and Exchange Commission ("SEC") under the Securities Exchange Act of 1934.

Transfer Restrictions

There are no restrictions imposed by the Company on the transfer of its outstanding Common Stock by the holders thereof, except as may be required under SEC Rule 144 with respect to restricted or control securities. Of the 22,016,059 shares of Company common stock currently outstanding, approximately 5,800,000 shares are held by affiliates and subject to transfer restrictions as control securities.

Suspension Orders Issued by the SEC in the Past 12 Months

There have not been any suspension orders issued with respect to the trading of the Company's common stock during the past 12 months or at any other time in the past. The Company's shares have traded publicly since 1991.

4) Issuance History

The Company issued 61,250 shares to a consultant for services rendered in March 2018.

5) Financial Statements

The Company's audited financial statements for the quarter ended March 31, 2018, which were posted to www.otcmarkets.com May 15, 2018, are incorporated herein by this reference.

As explained in Note 6 to the financial statements, as of October 1, 2014, the Company's accumulated deficit of $24,556,683 was restated to zero and its common stock account was reduced by the same amount from $25,166,313 to $609,630. This readjustment of the accumulated deficit and reclassification of the capital account is known as a quasi-reorganization or accounting restructuring and is permitted under US GAAP pursuant to Accounting Standards Codification ("ASC") 852-20-25.

Most of the accumulated deficit occurred prior to 1994. To implement the quasi-reorganization, the Company had to show through financial results or modified operations that it had fully recovered from the years when the deficit was incurred and that it had obtained approval of the restructuring from its board of directors and shareholders.

The Company's prior management was replaced and the management structure reorganized from 1995 through 1999. New management modified the Company's prior operational strategy and from October 1, 2009 to September 30, 2014, the Company had five consecutive fiscal years of profitable operations. As a result, the Board of Directors determined that the Company had met the requirements of ASC 852-20-25 and the quasi-reorganization was made effective as of October 1, 2014. The Company remained profitable in fiscal 2015 and 2016.

6) Describe the Issuer's Business, Products and Services

Products and Services

The Company produces and sells in vitro assay kits to detect, rank and predict the potential level of irritancy, toxicity or corrosivity of substances on human eye (ocular) and/or skin tissue (dermal). It sells its products direct to customers, independent partner laboratories, and agents in the United States, Europe, Latin America and Asia. It also conducts laboratory testing for those customers who prefer not to conduct their own tests.

An 'in vitro" assay measures a substance of clinical interest without the use of live animal tissue. In vitro is Latin for "within the glass." Tests using live animal tissue are known as "in vivo" (Latin for "within the living"). Toxicity testing traditionally required the use of live animals or living animal tissue as a means of predicting the effect of various substances on human tissue. In recent years, in vitro tests have become accepted substitutes for some in vivo testing due to increased social concerns of using animals as test subjects, provided the in vitro tests can be validated statistically to be as accurate as in vivo testing.

The Company sells three proprietary in vitro products: (1) Ocular IRRITECTION® used to evaluate the potential for ocular irritation; (2) IRRITECTION® Dermal used to evaluate the potential for dermal irritation; and (3) CORROSITEX™ used to determine corrosivity level classifications within regulatory guidelines that are applicable to the transport and storage of chemicals, formulations and hazardous waste.

These unique assays are principally used by manufacturers to verify product safety of consumer, household and industrial products, to comply with transportation and environmental regulations and to assist in evaluation of workplace safety.

The CORROSITEX™ assay has been marketed since 1991 and the IRRITECTION® assays have been marketed since 1989. All three test methods are currently marketed by Company internal personnel through industry contacts, standard advertising and a strategic alliance with INT.E.G.RA, a division of Italy based Res Pharma, which sells and distributes the Company's test kits and laboratory testing services in Italy and 21 other countries around the

world. The Company is also in the process of developing a targeted social media marketing program.

When compared to conventional animal testing, the Company's test methods require significantly less time, produce quantitative results which are consistently reproducible, cost effective, and are more humane. Through use of its testing technologies, the Company has accumulated a database of several thousand chemicals and formulations tested that validate the efficacy of the Company's proprietary methodology when compared to in vivo testing.

Transportation Regulations -Background

The United Nations ("UN") has guidelines for classifying corrosive substances into four Packing Groups (Groups I, II or III), and noncorrosive. These groups are known as the UN Packing Groups. The UN guidelines have been implemented as regulations by the United States Department of Transportation ("DOT"). Shippers must certify the proper Packing Group classification for their materials to their packaging supplier and must use packaging and markings that comply with the regulations. Packaging, labeling and transportation requirements are more stringent and expensive for substances classified as Packing Group I or II than for Packing Group III or noncorrosive materials. Proper packaging is required to comply with DOT regulations to avoid fines and/or civil liability in the event of an accident or spill while the materials are in transit and to permit safer cleanup in the event of a spill.

In addition to UN Packing Groups, the UN also has set guidelines for ensuring the safe production, transport, handling, use and disposal of hazardous materials known as the Globally Harmonized System for Classification and Labeling of Chemicals ("GHS"). The United States' Occupational Safety & Health Administration ("OSHA") adopted GHS in 2012. Fourteen additional countries have also adopted GHS and other countries are in the process of considering adoption. There is no set time during which countries must adopt GHS. Utilizing the Company's CORROSITEX™ assay enables manufacturers to comply with GHS and UN Packaging Groups.

Recent Developments

In late 2014, the Company's Corrositex™ assay became GHS accepted as a full replacement for animal test results. The Organization for Economic Co-Operation and Development ("OECD"), which is comprised of 35 member countries, Transport Canada, DOT, OSHA, the Consumer Product Safety Commission, the Federal Drug Administration and the International Air Transport Authority have also accepted Corrositex™ as a full replacement test. OECD determined that CORROSITEX™ is the only non-animal corrosivity test which classifies, with 96%+ accuracy, U.N. Packing Groups I, II, III, and noncorrosive as well as their GHS equivalents.

In late 2015, the European Regulatory Program to re-classify all chemicals used in Europe accepted the Company's CORROSITEX™ test method as a full replacement for animal testing.

As a result of the OECD Expert Committee meeting in November 2017, the Company's Ocular IRRITECTION® test method has now moved on to the next phase of the OECD adoption process for acceptance as a substitute for animal testing on all future cosmetic products. A draft test guideline was submitted for review in June.

Technology

The Company's proprietary technology for eye and skin irritation testing is based upon the formulation of protein reagents used in conjunction with a porous membrane disc delivery system. This delivery system allows test substances to gradually diffuse and come into contact with the reagent. When exposed to potentially toxic or irritating compounds, the protein reagents become opaque and, accordingly, mimic the biochemical reactions of proteins found in human eye and skin cells that are injured by irritant substances. Results are objectively measured and quantified using an adapted plate reader and proprietary software developed by the Company.

The proprietary Corrositex™ technology is based upon a similar bio-barrier membrane system and a chemical detection system. When exposed to a corrosive substance, the time to permeate a bio-barrier membrane is correlated with the degree of tissue injury that would occur in a standard in vivo corrosives test. When a corrosive substance permeates the bio-barrier membrane, it causes a color change in the chemical detection system, thereby enabling the membrane "breakthrough" time to be determined.

Proprietary Rights

The Company maintains trade secrets and also holds trademarks in the United States and abroad.

Legal Proceedings

The Company may be a party to legal proceedings from time to time in the ordinary course of its business. No such proceedings are pending at the present time.

Miscellaneous

The Company was incorporated in California on September 19, 1985. Its fiscal year end is September 30 and its Primary Standard Industrial Code ("SIC") is 2835. It does not have a secondary SIC.

7) Describe the Issuer's Facilities

The Company leases approximately 4,100 square feet at 330 E. Orangethorpe Avenue, Suite D, Placentia, CA 92870 for its corporate headquarters. The facility consists of corporate offices, a testing laboratory, kit assembly space and warehouse space. It is leased from an unaffiliated third party for a term expiring on August 31, 2019. The lease currently provides for monthly rent of $3,215. Rent will increase on May 1, 2018 to $3,311 and on May 1, 2019 to

$3,410. The Company has no other facilities. It believes its current facilities are adequate to accommodate its foreseeable requirements.

The Company's test kits are assembled and packaged at its facility in Placentia and all laboratory tests for customers are performed at this facility. The materials and supplies used by the Company in assembling test kits and performing laboratory tests consist of both proprietary synthetic protein matrices and standard laboratory materials and instruments. The materials and instruments are readily available from suppliers. The Company keeps a limited inventory of raw materials on hand.

8) Officers, Directors and Control Persons

Names of Officers, Directors and Control Persons

Directors

W. Richard Ulmer
Irwin J. Gruverman
Dennis E. Chenoweth
Rolf E. Kleiner
Sean Adrean

Officers

Name	Position
Rolf E. Kleiner	President
W. Richard Ulmer	CEO
Irwin J. Gruverman	Chairman of the Board
Cathy L. Richmond	Chief Financial Officer

Rolf Kleiner, Director, assumed the position of President of InVitro International, and Rich Ulmer will remain CEO effective February 1, 2018. Rich's position will be working remotely in a support role. He will be responsible for overall company financial strategy along with investor, government and public relations. He will also support Rolf on matters regarding new sales opportunities and existing customer support needs. Rolf will assume operational activities to include lab service, kit production, business development, sales & marketing, QA, and overall P&L. He will weigh in heavily on overall business strategy, R&D and financial reporting.

InVitro is pleased to announce the addition of Sean Adrean, M.D., F.A.A.O to InVitro's Board of Directors effective April 1, 2018. Sean is a leader in retinal clinical studies and technologies for his Private Retinal Consultation Practice, Retina Consultants of Orange County. His expertise in eye care is relevant to InVitro's products and services offerings. InVitro welcomes Sean to the Board and we look forward to his contributions.

Control Persons

W. Richard Ulmer and Irwin J. Gruverman are each beneficial owners of more than 5% of the Company's outstanding Common Stock.

Legal/Disciplinary History

None of the foregoing persons have in the past five years, or at any prior time thereto been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

3. A finding or judgment by a court of competent jurisdiction (in a civil action) , the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or
4. The entry of an order by a self-regulatory organization that permanently or temporarily barred suspended or otherwise limited such person's involvement in any type of business or securities activities.

Beneficial Shareholders Holding More Than 10% of the Outstanding Shares

Name	Address	Number of Shares of Common Stock
W. Richard Ulmer	18550 Martinique Ct. Villa Park, CA 92861	2,800,000

9) Third Party Providers

Legal Counsel

Haddan & Zepfel LLP
610 Newport Center Drive, Suite 330
Newport Beach, CA 92660
949-706-6000 jrh@haddanzepfel.com

Accountant or Auditor

PDM, LLP
3460 Torrance Blvd., Suite 200
Torrance, CA 90503 310-540-4118

abozanic@pdmcpas.com

Investment Relations Consultant

None currently.

Other Advisor

No other advisor has assisted, advised prepared or provided information with respect to this disclosure statement.

10) Issuer Certifications

I, Rolf E. Kleiner, certify that:

1. I have reviewed this quarterly disclosure statement of InVitro International:

2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

/s/ Rolf E. Kleiner
President

I, Cathy L. Richmond, certify that:

1. I have reviewed this quarterly disclosure statement of InVitro International:

2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

/s/ Cathy L. Richmond
Chief Financial Officer